Author: Dr. Nikhilesh R. Sekhar, MD, FACS, FASMBS The FDA approval of the first oral GLP-1 medication for obesity marks an important shift in medical weight loss treatment. Patients now have access to a non injectable option that can produce clinically meaningful weight loss, improve cardiovascular risk, and reduce monthly costs compared with injectable GLP-1 medications. While this new weight loss pill expands access and convenience, it does not replace bariatric surgery. Surgery remains the most effective and durable treatment for obesity and obesity related medical conditions. At New York Bariatric Group, our goal is not to push one solution,” […] The post FDA Approves First GLP-1 Weight Loss Pill. What Patients Need to Know appeared first on New York Bariatric Group.
Author: Dr. Nikhilesh R. Sekhar, MD, FACS, FASMBS
The FDA approval of the first oral GLP-1 medication for obesity marks an important shift in medical weight loss treatment. Patients now have access to a non injectable option that can produce clinically meaningful weight loss, improve cardiovascular risk, and reduce monthly costs compared with injectable GLP-1 medications.
While this new weight loss pill expands access and convenience, it does not replace bariatric surgery. Surgery remains the most effective and durable treatment for obesity and obesity related medical conditions.
At New York Bariatric Group, our goal is not to push one solution,” says Dr. Nikhilesh Sekhar, bariatric surgeon at New York Bariatric Group. “It is to help patients choose the option that gives them the best chance at long term health.”
What Is the New GLP-1 Weight Loss Pill
The newly approved GLP-1 pill is an oral form of semaglutide, the same medication used in injectable Wegovy. It works by reducing appetite, slowing gastric emptying, improving insulin sensitivity, and increasing feelings of fullness.
In clinical trials, patients taking the highest dose achieved up to 16.6 percent excess weight loss (EWL) over 64 weeks. Average excess weight loss across all participants was approximately 13.6 percent EWL.
These results are comparable to injectable GLP-1 medications.
Why the GLP-1 Pill Matters for Weight Loss Patients
Many patients avoided GLP-1 medications because they did not want injections or could not afford them. Oral therapy lowers those barriers.
Key benefits include daily oral dosing, lower out of pocket cost compared with injectables, wide pharmacy and telehealth availability, and FDA approval that includes cardiovascular risk reduction.
“The approval of an oral GLP-1 medication improves access,” Dr. Sekhar explains. “That is meaningful progress for obesity care.”
Who Is a Good Candidate for a GLP-1 Weight Loss Pill
The GLP-1 pill may be appropriate for patients who prefer oral medication instead of injections, have mild to moderate obesity, are early in their weight loss journey, and can follow strict daily dosing and fasting instructions.
Daily oral dosing requires consistency and timing, which may limit suitability for some patients.
Limitations of GLP-1 Weight Loss Medications
GLP-1 medications are effective only while they are being taken.
“When patients stop the medication, weight regain is common,” says Dr. Sekhar. “That is not a failure of the patient. It is how the biology works.”
Additional limitations include the need for long term or lifelong use, ongoing monthly costs, potential insurance changes, and less reliable improvement in severe diabetes, sleep apnea, or reflux.
Bariatric Surgery for Long Term Weight Loss
Bariatric surgery remains the most effective treatment for obesity.
Most patients achieve 50 to 70 percent excess weight loss (EWL) with long term durability. Surgery also offers high rates of improvement or remission of type 2 diabetes, high blood pressure, sleep apnea, and gastroesophageal reflux disease.
“Bariatric surgery changes the underlying physiology,” Dr. Sekhar says. “It consistently delivers greater and more durable excess weight loss.”
GLP-1 Pill vs Bariatric Surgery
GLP-1 pills typically result in 13 to 17 percent excess weight loss while the medication is continued. Bariatric surgery produces significantly greater excess weight loss with long term durability.
Medication therapy requires continuous use and ongoing cost. Bariatric surgery is a one time intervention with lasting metabolic benefits.
“This is not medication versus surgery,” Dr. Sekhar explains. “The right treatment depends on the patient’s health history and long term goals.”
New York Bariatric Group Approach to Obesity Care
At New York Bariatric Group, obesity treatment is personalized and evidence based.
Some patients benefit from medication as a first step. Others require surgery for durable metabolic control. Many patients benefit from a combination approach over time.
“Our role is to guide patients honestly,” Dr. Sekhar says. “The goal is long term health, not short term weight loss.”
The post FDA Approves First GLP-1 Weight Loss Pill. What Patients Need to Know appeared first on New York Bariatric Group.
